CB-618

• Description :

  CB-618 is a β-lactamase inhibitor. CB-618 reversibly covalently inhibits Ambler class A, C, and some class D serine β-lactamases. CB-618 has weak antibacterial activity as a single agent, but it significantly enhances the antibacterial activity of Meropenem (HY-13678) against enzyme-producing Enterobacteriaceae. CB-618 can be used in research on drug-resistant bacteria[1][2].

• UNSPSC :

  12352005

• Target :

  Bacterial; Beta-lactamase

• Related Pathways :

  Anti-infection

• Field of Research :

  Infection

• Smiles :

  O=S(ON1[C@]2([H])CC[C@@H](C3=NN=CO3)[N@@](C2)C1=O)(O)=O

• Molecular Formula :

  C8H10N4O6S

• Molecular Weight :

  290.25

• References & Citations :

  [1]Papp-Wallace KM, Bonomo RA. New β-lactamase inhibitors in the clinic. Infectious disease clinics of North America. 2016 Jun;30 (2) :441.|[2]Griffith DC, et al. Pharmacokinetics/pharmacodynamics of vaborbactam, a novel beta-lactamase inhibitor, in combination with meropenem. Antimicrobial Agents and Chemotherapy. 2019 Jan;63 (1) :10-128.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1463520-70-8]